Healthcare entity

Zentaris IVF GmbH

Company

All 1 tracked stories fall under one category: market-trends. Aeterna Zentaris GmbH is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.

Last mentioned: Mar 6, 2026

Entity pulse

Recent coverage · Zentaris IVF GmbH

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Zentaris IVF GmbH

All 1 tracked stories fall under one category: market-trends. Aeterna Zentaris GmbH is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention Zentaris IVF GmbH, all published on March 6, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Zentaris IVF GmbH. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Strategic Update

    COSCIENS announces cessation of funding for German subsidiaries and expected insolvency.

  2. FDA Type C Meeting

    Company meets with FDA to discuss disappointing DETECT trial results and pediatric path forward.

  3. DETECT Trial Results

    Phase 3 trial for Macrilen pediatric indication fails to meet primary endpoints.

  4. Wuzhou Distribution Deal

    COSCIENS signs distribution agreement with Wuzhou Drug International Trading Limited.

Stories mentioning Zentaris IVF GmbH 1

Market Trends Neutral

COSCIENS Biopharma Abandons German Units Following Macrilen Pediatric Setback

COSCIENS Biopharma Inc. (TSX: CSCI) has announced a strategic cessation of funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, effectively triggering an insolvency process. This decision follows a critical failure in the Phase 3 DETECT trial for Macrilen’s pediatric indication and a subsequent setback in FDA negotiations.

2 sources

Source: GlobeNewswire (ca) · CBJ (ca)

Zentaris IVF GmbH is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.